ATP7B and neoplasm: found that mutations in the first 5 N-terminal copper-binding sites of ATP7B did not inhibit the cisplatin-induced catalytic phosphorylation of ATP7B and that deletion of the first four copper-binding sites abolishes the effect of cisplatin on ATP7B activity, suggesting this direct binding of cisplatin to ATP7B plays a role in tumor resistance to cisplatin.